CN112315926A - Valsartan oral solid preparation - Google Patents
Valsartan oral solid preparation Download PDFInfo
- Publication number
- CN112315926A CN112315926A CN202011318917.8A CN202011318917A CN112315926A CN 112315926 A CN112315926 A CN 112315926A CN 202011318917 A CN202011318917 A CN 202011318917A CN 112315926 A CN112315926 A CN 112315926A
- Authority
- CN
- China
- Prior art keywords
- valsartan
- oral solid
- solid preparation
- pharmaceutically acceptable
- calcium carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
Abstract
The invention relates to the technical field of biological medicines, and in particular relates to a valsartan oral solid preparation which comprises valsartan and pharmaceutically acceptable salts thereof, calcium carbonate and other pharmaceutically acceptable auxiliary materials. The calcium carbonate is added into the valsartan oral solid preparation provided by the invention, so that the release of the medicament is promoted and the bioavailability of valsartan disodium salt in the stomach is increased under low pH compared with a valsartan or a valsartan/Sacubitril compound oral solid preparation without calcium carbonate.
Description
Technical Field
The invention relates to the technical field of biological medicines, and in particular relates to a valsartan oral solid preparation.
Background
Valsartan has been used since the 90 s of the nineteenth century to treat hypertension, congestive heart failure, myocardial infarction, and other conditions. Valsartan belongs to an angiotensin II receptor antagonist antihypertensive drug, and the drug enables an angiotensin II type I (AT1) receptor to be blocked, the blood plasma concentration of angiotensin II is increased, the unblocked AT2 receptor is stimulated, and the effect of AT1 receptor is resisted, so that the effects of expanding blood vessels and reducing blood pressure are achieved. After valsartan drug, named as Diovan, is marketed in the United states and becomes the 85 th most commonly prescribed drug in the United states, more products are introduced to the market, which act together with other active ingredients, such as valsartan or valsartan disodium.
Valsartan belongs to the third class of drugs according to the biopharmaceutical classification system. It has low solubility and high permeability. The solubility of valsartan varies with the ph of the medium. In a physiological environment with high pH value, such as an environment with a pH value of 6.8, the valsartan disodium salt can be freely dissolved. As the pH is lowered, especially when the pH is lowered from 4.0 to 1.0, the solubility of valsartan decreases significantly until it is almost insoluble. Valsartan has two weak acid radicals with dissociation constants of 3.9 and 4.7. Therefore, in a hydrochloric acid environment with low pH value such as 0.1N, most of the valsartan disodium salt is converted into valsartan monosodium salt and an undissociated acid of valsartan, so that the solubility and the disintegration are reduced, and the absorption of the drug is hindered.
The existing valsartan/sabotabifid compound oral solid preparation is generally prepared by preparing valsartan monomer or salt thereof into various types of crystalline forms, for example, patent applications WO2002006253, WO2004083192, WO2007017897, US20080261959, WO2003089417, WO2006076561, WO2003066606 and WO200206253 describe several types of solid forms of valsartan or pharmaceutically acceptable salt thereof. As a general matter, the salt form of valsartan may be selected from sodium salt, calcium salt, cyclohexylammonium salt and the like. However, the existing valsartan/Sacubitril compound oral solid preparation is usually low in solubility and disintegration in a low pH environment, and the absorption of the medicine is poor.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: provided is a valsartan oral solid preparation having high solubility and disintegration under a low pH environment.
The technical scheme for solving the technical problems is as follows:
the invention provides a valsartan oral solid preparation in a first aspect, which comprises valsartan and pharmaceutically acceptable salts thereof, calcium carbonate and other pharmaceutically acceptable auxiliary materials. The other pharmaceutically acceptable auxiliary materials refer to other auxiliary materials except calcium carbonate. Specifically, the pharmaceutically acceptable salt of valsartan refers to a sodium salt of valsartan; further, the pharmaceutically acceptable salt of valsartan refers to valsartan disodium salt.
Preferably, the mass percentage of the valsartan and the pharmaceutically acceptable salt thereof in the valsartan oral solid preparation is 1-80%; furthermore, the mass percentage of the valsartan and pharmaceutically acceptable salts thereof in the valsartan oral solid preparation is 20-60%; furthermore, the mass percentage of the valsartan and the pharmaceutically acceptable salt thereof in the valsartan oral solid preparation is 22-56%.
In a preferred embodiment of the invention, the mass percentage of the valsartan and the pharmaceutically acceptable salt thereof in the valsartan oral solid preparation is 22-29%.
Preferably, the weight percentage of calcium carbonate in the valsartan oral solid preparation is 1-90%; further, the weight percentage of calcium carbonate in the valsartan oral solid preparation is 1-50%; furthermore, the weight percentage of calcium carbonate in the valsartan oral solid preparation is 1-35%; still further, the weight percentage of calcium carbonate in the valsartan oral solid preparation is 1-10%.
In a preferred embodiment of the invention, the weight percentage of the calcium carbonate in the valsartan oral solid preparation is 7-10%.
The mass percent of the calcium carbonate refers to the mass percent of the calcium carbonate alone; or the mass percentage of other calcium carbonate-containing materials.
Preferably, the valsartan oral solid preparation further comprises a filler, a disintegrant and a lubricant, and other auxiliary materials for assisting the formation of the preparation; specifically, fillers include, but are not limited to, microcrystalline cellulose, lactose monohydrate, mannitol; disintegrants include, but are not limited to, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, sodium carboxymethyl starch; lubricants include, but are not limited to, colloidal silicon dioxide, talc, magnesium stearate; other excipients that aid in the formation of the formulation include, but are not limited to, binders, colorants, surfactants, and the like.
The invention provides a valsartan/sabotabifrazole compound oral solid preparation, which comprises valsartan and pharmaceutically acceptable salts thereof, sabotabifrazole and pharmaceutically acceptable salts thereof, calcium carbonate and other pharmaceutically acceptable auxiliary materials. The other pharmaceutically acceptable auxiliary materials refer to other auxiliary materials except calcium carbonate. Specifically, the pharmaceutically acceptable salt of valsartan refers to a sodium salt of valsartan; further, the pharmaceutically acceptable salt of valsartan refers to valsartan disodium salt.
Preferably, the mass percentage of the valsartan and the pharmaceutically acceptable salts thereof in the valsartan/Sacubitril compound oral solid preparation is 1-80%; furthermore, the mass percentage of the valsartan and the pharmaceutically acceptable salts thereof in the valsartan/Sacubitril compound oral solid preparation is 10-60%.
In a preferred embodiment of the invention, the mass percentage of valsartan and pharmaceutically acceptable salts thereof in the valsartan oral solid preparation is 22-56%.
Preferably, the mass percentage of the valsartan/sabotabetrol compound oral solid preparation to the sabotabetrol and the pharmaceutically acceptable salts thereof is 1-80%; furthermore, the mass percentage of the valsartan/sabotabetrol compound oral solid preparation and the pharmaceutically acceptable salt thereof is 1-40%; furthermore, the mass percentage of the valsartan/sabotabetrol compound oral solid preparation and the pharmaceutically acceptable salt thereof is 10-30%.
In a preferred embodiment of the invention, the mass percentage of the valsartan/sabotaltrex compound oral solid preparation is 19-24% of the sabotaltrex and the pharmaceutically acceptable salts thereof.
Preferably, the weight percentage of calcium carbonate in the valsartan/Sacubitril compound oral solid preparation is 1-90%.
Further, the weight percentage of calcium carbonate in the valsartan/Sacubitril compound oral solid preparation is 1-70%;
furthermore, the weight percentage of calcium carbonate in the valsartan/Sacubitril compound oral solid preparation is 1-20%;
further, the weight percentage of calcium carbonate in the valsartan/Sacubitril compound oral solid preparation is 1-10%;
in a preferred embodiment of the invention, the mass percentage of calcium carbonate in the valsartan/Sacubitril compound oral solid preparation is 7-10%.
The mass percent of the calcium carbonate refers to the mass percent of the calcium carbonate alone; or the mass percentage of other materials containing calcium carbonate is preferred, the valsartan/Sacubitril compound oral solid preparation also comprises a filler, a disintegrant and a lubricant, and other auxiliary materials for assisting the formation of the preparation; specifically, fillers include, but are not limited to, microcrystalline cellulose, lactose monohydrate, mannitol; disintegrants include, but are not limited to, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, sodium carboxymethyl starch; lubricants include, but are not limited to, colloidal silicon dioxide, talc, magnesium stearate. Other excipients that aid in the formation of the formulation include, but are not limited to, binders, colorants, surfactants, and the like.
In a third aspect of the invention, there is provided the use of calcium carbonate for the manufacture of an oral solid formulation comprising valsartan and pharmaceutically acceptable salts thereof. The application specifically relates to the preparation of an oral solid preparation containing valsartan and pharmaceutically acceptable salts thereof by taking calcium carbonate as an auxiliary material. The oral solid preparation comprises oral solid or compound oral solid preparations such as double-layer tablets, capsules, granules, powder and the like.
The inventor surprisingly found that the addition of calcium carbonate promotes the release of the drug and increases the bioavailability of valsartan sodium salt in the stomach at low pH (corresponding to the pH conditions in the stomach) compared to valsartan or valsartan/sabotatory biqu compound oral solid formulations without calcium carbonate.
The Chinese naming of the compound of the invention conflicts with the structural formula, and the structural formula is taken as the standard; except for obvious errors in the formula.
The calcium carbonate is added into the valsartan oral solid preparation provided by the invention, so that the release of the medicament is promoted and the bioavailability of valsartan disodium salt in the stomach is increased under low pH compared with a valsartan or a valsartan/Sacubitril compound oral solid preparation without calcium carbonate.
Detailed Description
The invention is illustrated but not limited by the following examples. The technical solutions protected by the present invention are all the simple replacements or modifications made by the skilled person in the art.
Example 1:
TABLE 1
| Composition (I) | Mass content |
| Valsartan disodium | 29％ |
| Sacubitril sodium salt | 24％ |
| Ground calcium carbonate | 10％ |
| Crosslinked polyvinylpyrrolidone | 7％ |
| Mannitol | 10％ |
| Microcrystalline cellulose | 17％ |
| Colloidal silica | 2％ |
| Magnesium stearate | 1％ |
Tablets were prepared by conventional methods according to the formulation of table 1.
The preparation process comprises the following steps: the valsartan disodium, the sabotatory sodium, the ground calcium carbonate, the cross-linked polyvinylpyrrolidone, the mannitol, the colloidal silicon dioxide and the microcrystalline cellulose are mixed and sieved by a 30-mesh sieve, then are uniformly mixed, and the magnesium stearate sieved by a 40-mesh sieve is added and is uniformly mixed, and then tabletting is carried out.
Example 2:
TABLE 2
| Composition (I) | Mass content |
| Valsartan disodium | 22％ |
| Sacubitril sodium salt | 19％ |
| Starch granulated calcium carbonate granules | 7％ |
| Crosslinked carboxymethyl cellulose | 10％ |
| Lactose monohydrate | 16％ |
| Microcrystalline cellulose | 22％ |
| Colloidal silica | 1％ |
| Talcum powder | 2％ |
| Magnesium stearate | 1％ |
The preparation process comprises the following steps: the valsartan disodium, the sabotatory sodium, the cross-linked carboxymethyl cellulose, the lactose monohydrate, the microcrystalline cellulose, the colloidal silicon dioxide and the talcum powder are mixed and sieved by a 30-mesh sieve, and then the calcium carbonate particles granulated by starch are added and mixed uniformly. Adding magnesium stearate sieved by a 40-mesh sieve, uniformly mixing, and tabletting.
Example 3:
TABLE 3
The preparation process comprises the following steps: the valsartan disodium, the sabotai sodium, the light calcium carbonate, the sodium carboxymethyl starch, the lactose monohydrate, the microcrystalline cellulose and the colloidal silicon dioxide are mixed and sieved by a 30-mesh sieve, and then the mixture is uniformly mixed. Adding magnesium stearate sieved by a 40-mesh sieve, uniformly mixing, and tabletting.
Example 4:
TABLE 4
| Composition (I) | Mass content |
| Valsartan disodium | 56％ |
| Light calcium carbonate | 9％ |
| Crosslinked polyvinylpyrrolidone | 3％ |
| Mannitol | 10％ |
| Microcrystalline cellulose | 16％ |
| Colloidal silica | 2％ |
| Talcum powder | 3％ |
| Magnesium stearate | 1％ |
The preparation process comprises the following steps: the valsartan disodium, the light calcium carbonate, the cross-linked polyvinylpyrrolidone, the mannitol, the microcrystalline cellulose, the colloidal silicon dioxide and the talcum powder are mixed and sieved by a 30-mesh sieve, and the mixture is uniformly mixed. Adding magnesium stearate sieved by a 40-mesh sieve, uniformly mixing and tabletting.
Comparative example 1:
TABLE 5
| Composition (I) | Mass content |
| Valsartan disodium | 29％ |
| Sacubitril sodium salt | 24％ |
| Crosslinked polyvinylpyrrolidone | 6％ |
| Mannitol | 11％ |
| Microcrystalline cellulose | 25％ |
| Colloidal silica | 4％ |
| Magnesium stearate | 1％ |
Tablets were prepared by conventional methods according to the formulation of table 1.
The preparation process comprises the following steps: the valsartan disodium, the sabotatory sodium, the cross-linked polyvinylpyrrolidone, the mannitol, the colloidal silicon dioxide and the microcrystalline cellulose are mixed and sieved by a 30-mesh sieve, then are uniformly mixed, and the magnesium stearate sieved by a 40-mesh sieve is added and is uniformly mixed, and then tabletting is carried out.
Comparative example 2:
TABLE 6
The preparation process comprises the following steps: the valsartan disodium, the cross-linked polyvinylpyrrolidone, the mannitol, the microcrystalline cellulose, the colloidal silicon dioxide and the talcum powder are mixed and sieved by a 30-mesh sieve, and the mixture is uniformly mixed. Adding magnesium stearate sieved by a 40-mesh sieve, uniformly mixing and tabletting.
The raw materials used in the specific embodiment are all commercially available products, wherein the calcium carbonate is commercially available from the sources shown in table 5:
TABLE 7
The specific operation process of the dissolution experiment is as follows:
firstly, dissolution medium: 900 ml of 0.1N aqueous hydrochloric acid solution at 37 ℃;
② dissolution objects: each tablet contains about 113.40 mg of valsartan disodium (and/or about 102.18 mg of sabotabifrazole sodium)
Experimental method: adopting a basket method, rotating at 75 rpm; sampling times were 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45 minutes, and 60 minutes; about 5 ml of the solution was withdrawn per sampling point for the assay. The data of the dissolution test are shown in table 8, and the dissolution data shown in table 8 are all the dissolution data of valsartan disodium.
Table 8 results of prescription dissolution test (%)
| Example 1 | Example 2 | Example 3 | Example 4 | Comparative example 1 | Comparative example 2 | |
| 10 minutes | 0.8 | 0.8 | 1.1 | 0.2 | 0.0 | 0.0 |
| 15 minutes | 1.3 | 2.5 | 2.4 | 0.5 | 0.0 | 0.0 |
| 20 minutes | 1.9 | 3.0 | 3.9 | 1.2 | 0.0 | 0.0 |
| 30 minutes | 3.6 | 4.5 | 6.5 | 2.7 | 0.3 | 0.1 |
| 45 minutes | 4.9 | 8.6 | 7.7 | 4.1 | 0.3 | 0.2 |
| 60 minutes | 5.7 | 10.9 | 8.0 | 4.5 | 0.4 | 0.2 |
From the experiments, the calcium carbonate is added to improve the disintegration and dissolution of the valsartan or the valsartan/Sacubitril compound oral solid preparation under the acidic condition, and the valsartan or the valsartan/Sacubitril compound oral solid preparation is smoothly released in other solvents. The control hardly disintegrated, and therefore, almost no drug was dissolved from the data, whereas the tablets in examples 1 to 4 were smoothly disintegrated and dissolved due to the addition of calcium carbonate.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various changes and modifications can be made without departing from the inventive concept of the present invention, and these changes and modifications are all within the scope of the present invention.
Claims (15)
1. The valsartan oral solid preparation is characterized by comprising valsartan and pharmaceutically acceptable salts thereof, calcium carbonate and other pharmaceutically acceptable auxiliary materials.
2. The valsartan oral solid preparation according to claim 1, wherein the mass percentage of valsartan and the pharmaceutically acceptable salt thereof in the valsartan oral solid preparation is 1-80%.
3. The valsartan oral solid preparation according to claim 2, wherein the mass percentage of valsartan and the pharmaceutically acceptable salt thereof in the valsartan oral solid preparation is 20-60%.
4. The valsartan oral solid preparation according to claim 1, wherein the weight percentage of calcium carbonate in the valsartan oral solid preparation is 1-90%.
5. The valsartan oral solid preparation according to claim 4, wherein the weight percentage of calcium carbonate in the valsartan oral solid preparation is 1-50%.
6. The valsartan oral solid preparation according to claim 5, wherein the weight percentage of calcium carbonate in the valsartan oral solid preparation is 1-35%.
7. The valsartan oral solid preparation according to any one of claims 1 to 6, wherein the valsartan oral solid preparation further comprises a filler, a disintegrant and a lubricant, and other auxiliary materials for assisting the preparation forming; fillers include, but are not limited to, microcrystalline cellulose, lactose monohydrate, mannitol; disintegrants include, but are not limited to, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, sodium carboxymethyl starch; lubricants include, but are not limited to, colloidal silicon dioxide, talc, magnesium stearate, and other excipients that aid in formulation formation include, but are not limited to, binders, colorants, surfactants, and the like.
8. A valsartan/Sacubitril compound oral solid preparation is characterized by comprising valsartan and pharmaceutically acceptable salts thereof, Sacubitril and pharmaceutically acceptable salts thereof, calcium carbonate and other pharmaceutically acceptable auxiliary materials.
9. The valsartan/Sacubitril compound oral solid preparation according to claim 8, wherein the mass percentage of valsartan and pharmaceutically acceptable salts thereof in the valsartan/Sacubitril compound oral solid preparation is 1-80%.
10. The valsartan/Sacubitril compound oral solid preparation according to claim 9, wherein the mass percentage of valsartan and pharmaceutically acceptable salts thereof in the valsartan/Sacubitril compound oral solid preparation is 10-60%.
11. The valsartan/Sacubitril compound oral solid preparation according to claim 8, wherein the weight percentage of the valsartan/Sacubitril and the pharmaceutically acceptable salt thereof in the valsartan/Sacubitril compound oral solid preparation is 1-80%.
12. The valsartan/sabotazole compound oral solid preparation according to claim 11, wherein the mass percentage of the valsartan/sabotazole compound oral solid preparation is 1-40% of the weight percentage of the sabotazole and the pharmaceutically acceptable salts thereof.
13. The valsartan/Sacubitril compound oral solid preparation according to claim 8, wherein the weight percentage of calcium carbonate in the valsartan/Sacubitril compound oral solid preparation is 1-90%.
14. The valsartan/sabotazole compound oral solid preparation according to claim 13, wherein the weight percentage of calcium carbonate in the valsartan/sabotazole compound oral solid preparation is 1-70%.
15. Use of calcium carbonate for the preparation of an oral solid formulation comprising valsartan and pharmaceutically acceptable salts thereof.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011318917.8A CN112315926A (en) | 2020-11-23 | 2020-11-23 | Valsartan oral solid preparation |
| PCT/CN2021/096300 WO2022105168A1 (en) | 2020-11-23 | 2021-05-27 | Valsartan oral solid preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011318917.8A CN112315926A (en) | 2020-11-23 | 2020-11-23 | Valsartan oral solid preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112315926A true CN112315926A (en) | 2021-02-05 |
Family
ID=74321967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011318917.8A Pending CN112315926A (en) | 2020-11-23 | 2020-11-23 | Valsartan oral solid preparation |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112315926A (en) |
| WO (1) | WO2022105168A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022105168A1 (en) * | 2020-11-23 | 2022-05-27 | 常州制药厂有限公司 | Valsartan oral solid preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2067470A1 (en) * | 2007-12-03 | 2009-06-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions containing valsartan and process for its preparation |
| JP2014141518A (en) * | 2010-09-30 | 2014-08-07 | Shionogi & Co Ltd | Preparation for improving solubility of poorly soluble drug |
| CN105902506A (en) * | 2016-06-12 | 2016-08-31 | 佛山市腾瑞医药科技有限公司 | Sacubitril/valsartan preparation and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055181T2 (en) * | 2015-07-08 | 2021-11-29 | Hk Inno N Corp | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin |
| CN107510653A (en) * | 2016-06-17 | 2017-12-26 | 常州爱诺新睿医药技术有限公司 | It is a kind of containing unformed husky storehouse than bent and Valsartan Pharmaceutical composition of solid dispersions and preparation method thereof |
| CN112315926A (en) * | 2020-11-23 | 2021-02-05 | 常州制药厂有限公司 | Valsartan oral solid preparation |
-
2020
- 2020-11-23 CN CN202011318917.8A patent/CN112315926A/en active Pending
-
2021
- 2021-05-27 WO PCT/CN2021/096300 patent/WO2022105168A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2067470A1 (en) * | 2007-12-03 | 2009-06-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions containing valsartan and process for its preparation |
| JP2014141518A (en) * | 2010-09-30 | 2014-08-07 | Shionogi & Co Ltd | Preparation for improving solubility of poorly soluble drug |
| CN105902506A (en) * | 2016-06-12 | 2016-08-31 | 佛山市腾瑞医药科技有限公司 | Sacubitril/valsartan preparation and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 黄雅萍等: "缬沙坦片的制备工艺及质量一致性评价研究", 《药物评价研究》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022105168A1 (en) * | 2020-11-23 | 2022-05-27 | 常州制药厂有限公司 | Valsartan oral solid preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022105168A1 (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010316683B2 (en) | Tablet formulations of neratinib maleate | |
| EP3417861B1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| EP2058010B1 (en) | Pharmaceutical composition | |
| WO2020249001A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| NO316724B1 (en) | Basic stabilized composition of HMG-CoA reductase inhibitor | |
| KR20170139170A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
| EP2242483B1 (en) | Raloxifene composition | |
| CA2801020A1 (en) | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide | |
| WO2013026553A1 (en) | Composition comprising edoxaban | |
| AU2010250800A1 (en) | Oral compositions of celecoxib | |
| US20170231969A1 (en) | Pharmaceutical Compositions of Edoxaban | |
| WO2018041282A1 (en) | A pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof | |
| CN112315926A (en) | Valsartan oral solid preparation | |
| KR20100090138A (en) | Oral solid preparation for treatment and prevention of tuberculosis | |
| WO2010022580A1 (en) | Medical composition for treating hyperuricemia and the use thereof | |
| EA028969B1 (en) | Method for the prevention and/or treatment of cardiovascular diseases | |
| JP2814513B2 (en) | Pharmaceutical composition with improved dissolution | |
| US5091191A (en) | Pharmaceutical composition with improved dissolution property | |
| CN111803462A (en) | Pravastatin sodium enteric-coated tablet and preparation method thereof | |
| CN112057427A (en) | Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof | |
| KR101641319B1 (en) | Combined formulation with improved stability comprising ecabet and ranitidine | |
| RU2007147953A (en) | PHARMACEUTICAL RECIPES OF MICRONIZED (4-CHLOROPHENYL) [4- (4-pyridylmethyl) -phthalazin-1-yl] AND ITS SALTS WITH IMMEDIATE EXCESSION AND HIGH CONTENT | |
| EP4282415A1 (en) | A stable tablet composition of axitinib | |
| EP4302755A1 (en) | Palbociclib formulation containing an amino acid | |
| EP4302832A1 (en) | Palbociclib formulation containing glucono delta lactone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210205 |
|
| RJ01 | Rejection of invention patent application after publication |